Janus Henderson Group (NYSE:JHG – Free Report) had its price objective boosted by The Goldman Sachs Group from $36.00 to $37.00 in a research report released on Thursday morning, Benzinga reports. They currently have a sell rating on the stock. JHG has been the subject of a number of other reports. TD Cowen lifted their […]

Hamilton Lane (NASDAQ:HLNE – Free Report) had its price objective boosted by The Goldman Sachs Group from $139.00 to $147.00 in a report released on Thursday morning, Benzinga reports. The firm currently has a neutral rating on the stock. A number of other brokerages also recently issued reports on HLNE. UBS Group raised their price […]

JPMorgan Chase & Co. (NYSE:JPM) had its price target hoisted by Oppenheimer from $221.00 to $234.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an outperform rating on the financial services provider’s stock. Several other brokerages have also commented on JPM. StockNews.com raised JPMorgan Chase & Co. from […]

Wells Fargo & Company initiated coverage on shares of Verona Pharma (NASDAQ:VRNA – Free Report) in a research note released on Thursday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $50.00 target price on the stock. A number of other research analysts have also recently commented on VRNA. Truist Financial boosted their […]

T. Rowe Price Group (NASDAQ:TROW – Free Report) had its price objective decreased by The Goldman Sachs Group from $106.00 to $102.00 in a report issued on Thursday, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the asset manager’s stock. A number of other brokerages have also recently weighed in on […]

Upbound Group (NASDAQ:UPBD – Free Report) had its price target trimmed by Jefferies Financial Group from $37.00 to $35.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a hold rating on the stock. Several other brokerages have also issued reports on UPBD. BTIG Research began coverage on Upbound Group […]

HC Wainwright restated their buy rating on shares of Verona Pharma (NASDAQ:VRNA – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $36.00 price target on the stock. Other analysts have also issued research reports about the company. Canaccord Genuity Group increased their price objective on […]

Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) had its price objective raised by Truist Financial from $10.00 to $12.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock. A number of other research firms have also weighed in on AMRX. Barclays increased their target price on shares […]